Dulaglutide: indexed trial records

This page carries 12 of the 1,320 records the literature query returned for Dulaglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.

Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.

At a glance

Class

Incretin receptor agonists

Receptor targets as recorded

GLP-1 receptor

Records indexed here

12

Records returned by the query

1,320

Publication years covered

2019–2025

Query retrieved

2026-10-12

Shape of the indexed record set

Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.

Endpoint coverage

Derived record-set tier

Preparation or mixture (INFERRED, derived from record counts)
Basis: PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and it does not rank one compound above another.

What the corpus does not carry for this compound

• Identity fields with no source retrieved: cas, pubchem_cid, uniprot_id, molecular_formula, molecular_weight, sequence.
• Reported half-life: no source retrieved, so the value reads Unknown.
• Amounts reported in the cited literature: no row recorded.
• Adverse effects reported in the cited literature: no row recorded.
• Long-form mechanism: not written, because no source was read in full.
• Records the query returned that this corpus does not carry: 1,308.

An absent row records the absence of a retrieved report, never the absence of the thing itself.

Application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA125469, marketed as TRULICITY). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.^[1]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

The records

Where this page sits

Receptor targets

• GLP-1 receptor: every compound in scope acting at it

All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.

Review status

Review tier

High impact

State

Pending qualified review

Compiled by

automated pipeline

Qualified clinical review

None on record

Why this tier was assigned

• the name carries 1 Drugs@FDA application record(s), so readers may conflate it with an approved medicine
• 11 indexed record(s) are interventional human trials
• the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus

Checks the pipeline performed

• every cited source id resolves to a sources[] row on the entity
• every identifier is a well-formed PMID or DOI
• study model derived only from assigned MeSH headings and publication types
• banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
• unknown values render as the literal word Unknown

Checks the pipeline did not perform

• no full text was read
• no clinical appraisal of any study
• no assessment of whether the indexed set is representative of the literature

A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.

Sources

1. Drugs@FDA application register query for this compound, 1 application(s) returned: BLA125469. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:dulaglutide
2. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes care (2014). pmid:24842985
3. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes care (2014). pmid:24742660
4. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes care (2014). pmid:24879836
5. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet (London, England) (2014). pmid:25018121
6. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes care (2015). pmid:26089386
7. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology (2018). pmid:29483060
8. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England) (2019). pmid:31189511
9. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet (London, England) (2019). pmid:31189509
10. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. The Lancet. Neurology (2020). pmid:32562683
11. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet. Diabetes & endocrinology (2018). pmid:29910024
12. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology (2018). pmid:29397376